v3.23.2
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
Current assets:    
Cash $ 1,252 $ 357
Accounts receivable 21 9
Employee advance 5 0
Inventory, short term 189 336
Net investment in leases, short term 102 101
Prepaid expenses and vendor deposits4 418 325
Total current assets 1,987 1,128
Property and equipment, net 621 665
Right-to-use assets, net 561 705
Other assets:    
Inventory, long term 0 1,141
Net investment in leases, long term 69 120
Patents, net 298 307
Other assets 514 44
Total assets 4,050 4,110
Current liabilities:    
Accounts payable and accrued expenses, including $0 and $120 to related parties as of March 31, 2023 and December 31, 2022, respectively 2,906 2,852
Deferred revenue, short term 0 5
Dividends payable 96 91
Lease liability, short term 330 313
Total current liabilities 3,332 3,261
Lease liability, long term 282 452
Total long term liabilities 282 452
Total liabilities 3,614 3,713
Convertible Preferred Stock 105 105
Equity:    
Preferred stock 0 0
Common stock, $0.001 par value, authorized 200,000,000 shares, 66,857,687 and 54,610,638 issued and outstanding as of March 31, 2023 and December 31, 2022, respectively 73 55
Additional paid in capital 234,568 216,232
Accumulated deficit (234,399) (215,974)
Total stockholders' equity attributable to BioSig Technologies, Inc. 242 313
Non controlling interest 89 (21)
Total equity 331 292
Total liabilities and equity $ 4,050 $ 4,110

Source

PDF HTML
10-Q Filing
ZIP XLS
XBRL